<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

“I do believe things are looking really good for patients with DLBCL,” Dr. Manali Kamdar, a clinical researcher in the field of blood cancers at the University of Colorado Anschutz Medical Campus, tells us. Kamdar describes 2022 and 2023 as “pivotal in terms of having more medications approved for patients with large-cell lymphoma.”